SF3B1 and B-cell chronic lymphocytic leukemia: A CRISPR engineered Nalm-6 isogenic cell line pair expressing either endogenous SF3B1K700E or mutant SF3B1K700K was used to further assess the effect of the most frequent SF3B1 mutation, which has been reported to impair splicing in CLL [27].